Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of IGI Laboratories, Inc. Soared Today

By Brian Feroldi - Jul 24, 2015 at 12:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

IGI Laboratories stock surged more than 19% today after reporting second quarter results. Where results really good enough to justify such a strong move?

What: Shares of IGI Laboratories (TLGT), a specialty generic pharmaceutical company, soared more than 22% higher this morning after the company reported second quarter earnings last night.

So what: Revenue for the quarter jumped 37% year-over-year to $8.9 million, slightly ahead of the $8.89 million that analysts were expecting. On a GAAP basis, net loss for the quarter was -$0.04 per share, which was well ahead of the -$0.08 loss that analysts were expecting. 

The company reaffirmed revenue guidance for the full year to land between $35 and $40 million and also expects that gross margins will improve with each passing quarter. This should allow the company to approach a break-even operating margin by the fourth quarter.

In addition, the company is planning to submit up to 20 abbreviated new drug applications, or ANDAs, to the FDA by the end of the year. An ANDA is an application for a generic drug approval for an existing licensed medication or drug.

Now what: IGI was able to submit 6 new ANDA submissions to the FDA for approval during the quarter, bringing their total to 28 ANDAs currently pending approval. Combined, the company estimates that these 28 generic drugs represent a $1.2 billion market opportunity, which is a huge increase from the $702 million opportunity that the company was previously targeting from their ANDA submissions just last quarter

Although ANDAs can take a long time to get through the FDA, I think investors were right to cheer the news today, as a $1.2 billion market opportunity is simply massive for a company that is estimating full year revenue of just $35 to $40 million. 

With more than $150 million in cash on the balance sheet, the company appears to have plenty of capital to fund its research and development efforts needed to complete the additional ANDA filings. If IGI can manage to reach a break-even operating margin by the end of the year, it should put the company on solid financial footing, which could make the stock a very interesting investment opportunity, even after today's huge move.  

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teligent, Inc. Stock Quote
Teligent, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.